Search

Your search keyword '"Ludovica Vittoria Marfella"' showing total 3 results
Start Over Author "Ludovica Vittoria Marfella" Topic medicine.disease
3 results on '"Ludovica Vittoria Marfella"'

1. Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: The CAVEAT study

Author

Giovanni Napolitano, Gianpaolo Papaccio, Fabrizio Turriziani, Celestino Sardu, Marilena Galdiero, Antonio Papa, Luigi Salemme, Giuseppe Paolisso, Lucia Scisciola, Nicola Coppola, Eugenio Basile, Carmela Papa, Paolo Maggi, Michelangela Barbieri, Ferdinando Carlo Sasso, Ciro Romano, F. Russo, Maria Rosaria Rizzo, Maria Luisa Balestrieri, Raffaele Marfella, Mario Siniscalchi, Claudio Napoli, Vincenzo Messina, Nunzia D'Onofrio, Ludovica Vittoria Marfella, Maria Vittoria Montemurro, Italo F. Angelillo, Virginia Tirino, Marco Boccalatte, Francesco Frascaria, Mauro Maniscalco, Marfella, Raffaele, D'Onofrio, Nunzia, Sardu, Celestino, Scisciola, Lucia, Maggi, Paolo, Coppola, Nicola, Romano, Ciro, Messina, Vincenzo, Turriziani, Fabrizio, Siniscalchi, Mario, Maniscalco, Mauro, Boccalatte, Marco, Napolitano, Giovanni, Salemme, Luigi, Marfella, Ludovica Vittoria, Basile, Eugenio, Montemurro, Maria Vittoria, Papa, Carmela, Frascaria, Francesco, Papa, Antonio, Russo, Ferdinando, Tirino, Virginia, Papaccio, Gianpaolo, Galdiero, Marilena, Sasso, Ferdinando Carlo, Barbieri, Michelangela, Rizzo, Maria Rosaria, Balestrieri, Maria Luisa, Angelillo, Italo Francesco, Napoli, Claudio, Paolisso, Giuseppe, Marfella, R., D'Onofrio, N., Sardu, C., Scisciola, L., Maggi, P., Coppola, N., Romano, C., Messina, V., Turriziani, F., Siniscalchi, M., Maniscalco, M., Boccalatte, M., Napolitano, G., Salemme, L., Marfella, L. V., Basile, E., Montemurro, M. V., Papa, C., Frascaria, F., Papa, A., Russo, F., Tirino, V., Papaccio, G., Galdiero, M., Sasso, F. C., Barbieri, M., Rizzo, M. R., Balestrieri, M. L., Angelillo, I. F., Napoli, C., and Paolisso, G.

Subjects
Blood Glucose, medicine.medical_specialty, Glycated Hemoglobin A, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), COVID-19 Vaccine, Endocrinology, Diabetes and Metabolism, MEDLINE, Type 2 diabetes, Glycemic Control, Affect (psychology), Endocrinology, Immunogenicity, Vaccine, Internal medicine, Research Letter, Internal Medicine, medicine, Humans, In patient, Poor glycaemic control, Glycated Hemoglobin, business.industry, Immunogenicity, COVID-19, medicine.disease, Research Letters, Vaccination, Diabetes Mellitus, Type 2, business, Human
Published
2021

2. Author response for 'Does poor glycemic control affect the immunogenicity of COVID ‐19 vaccination in patients with Type 2 Diabetes: The CAVEAT study'

Author

Claudio Napoli, Fabrizio Turriziani, Giuseppe Paolisso, Giovanni Napolitano, Eugenio Basile, Vincenzo Messina, Marco Boccalatte, F. Russo, Michelangela Barbieri, Maria Rosaria Rizzo, Paolo Maggi, Maria Luisa Balestrieri, Luigi Salemme, Mauro Maniscalco, Raffaele Marfella, Italo F. Angelillo, Francesco Frascaria, Ludovica Vittoria Marfella, Gianpaolo Papaccio, Maria Vittoria Montemurro, Nunzia D'Onofrio, Ferdinando Carlo Sasso, Virginia Tirino, Carmela Papa, Marilena Galdiero, Lucia Scisciola, Antonio Papa, Mario Siniscalchi, Ciro Romano, Nicola Coppola, and Celestino Sardu

Subjects
Vaccination, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, Poor glycemic control, Internal medicine, Immunogenicity, medicine, In patient, Type 2 diabetes, medicine.disease, business, Affect (psychology)
Published
2021
Full Text
View/download PDF

3. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment

Author

Fabrizio Turriziani, Michelangela Barbieri, Maria Consiglia Trotta, Giuseppe Paolisso, Maria Luisa Balestrieri, Raffaele Marfella, Franca Ferraraccio, Lella Petrella, Iacopo Panarese, Ludovica Vittoria Marfella, Mara Fanelli, Ciro Mauro, Piero Modugno, Celestino Sardu, Lucia Scisciola, Fabio Minicucci, Ferdinando Carlo Sasso, Massimo Massetti, Maria Rosaria Rizzo, Nunzia D'Onofrio, Massimo Federici, Fulvio Furbatto, D'Onofrio, N., Sardu, C., Trotta, M. C., Scisciola, L., Turriziani, F., Ferraraccio, F., Panarese, I., Petrella, L., Fanelli, M., Modugno, P., Massetti, M., Marfella, L. V., Sasso, F. C., Rizzo, M. R., Barbieri, M., Furbatto, F., Minicucci, F., Mauro, C., Federici, M., Balestrieri, M. L., Paolisso, G., and Marfella, R.

Subjects
Male, medicine.medical_specialty, Cells, medicine.medical_treatment, Type 2 diabetes, Carotid endarterectomy, SGLT2, Gastroenterology, Sodium-Glucose Transporter 2, Diabetes mellitus, Internal medicine, Type 2 diabetes mellitus, Diabetes Mellitus, medicine, Humans, Hypoglycemic Agents, Myocardial infarction, Settore MED/23 - CHIRURGIA CARDIACA, Molecular Biology, Sodium-Glucose Transporter 2 Inhibitors, Cells, Cultured, Plaque, Atherosclerotic, Endarterectomy, Aged, Canagliflozin, Inflammation, Cultured, business.industry, Type 2 Diabetes Mellitus, Cell Biology, medicine.disease, Atherosclerosis, RC31-1245, Plaque, Atherosclerotic, Diabetes Mellitus, Type 2, Atherosclerosi, Female, Original Article, Sirtuin-6, business, Type 2, Mace, medicine.drug
Abstract

Objective We evaluated sodium-glucose co-transporter2 (SGLT2) expression and the effect of SGLT2 inhibitor (SGLT2i) therapies on carotid plaques of asymptomatic diabetic and non-diabetic patients. Methods Plaques were obtained from 296 non-diabetic patients and 227 patients with type 2 diabetes undergoing carotid endarterectomy. 97 patients with type 2 diabetes were treated with SGLT2 inhibitors for 16 ± 4 months before endarterectomy. After propensity score matching analysis, patients with type 2 diabetes were categorized without (n = 87) and with SGLT2i therapy (n = 87). To investigate SGLT2 expression levels' effects on major adverse endpoints (MACE = stroke, transient ischemic attack, myocardial infarction, and death), we evaluated MACE outcomes at a 2-year follow-up. Results Compared to plaques from patients without diabetes, plaques from patients with diabetes had higher SGLT2 expression, inflammation, and oxidative stress, along with lower SIRT6 expression and collagen content. Compared with plaques from patients with diabetes, SGLT2i-treated patients with type 2 diabetes presented increased SIRT6 expression and collagen content and lowered inflammation and ion and oxidative stress, thus indicating a more stable plaque phenotype. These results supported in vitro observations on human aorta endothelial cells (EC) (TeloHAEC-cells). Indeed, EC treated with high glucose (25 mM) in the presence of SGLT2i (100 nM canagliflozin) presented higher SIRT6 expression and decreased mRNA and protein SGLT2 levels, nuclear factor-kappa B (NF-B(NF-κB), and matrix metallopeptidase 9 (MMP-9) expression compared to cells treated only with high glucose. After two years following endarterectomy, a multivariable Cox regression analysis showed significantly higher 2-year overall survival from MACE in patients without diabetes (P, Highlights • The identification of novel molecular targets of atherosclerosis progression is of utmost importance in diabetic patients. • The occurrence of SGLT2 receptors on the endothelial cells of atherosclerotic plaques may be an attractive therapeutic option for atherosclerosis in patients with diabetes. • SGLT2/SIRT6 represents an attractive option, given its crucial involvement in atherosclerosis progression. • The endothelial SGLT2 inhibition increases the endothelial expression of SIRT6, yielding an improved atherosclerotic plaque phenotype and 2-year outcome. • The impairment of the endothelial SGLT2/SIRT6 pathway worsens outcomes in atherosclerotic patients with diabetes; this may be a potential preventive target.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results